J&J’s Dapoxetine Has Sound Safety Profile, But Will FDA Be Satisfied?
Executive Summary
Johnson & Johnson's investigative short acting selective serotonin reuptake inhibitor dapoxetine produced no reports of suicidality in Phase III trials for premature ejaculation
You may also be interested in...
Reviving The Premature Ejaculation Field; Sciele/Plethora Start Final Phase III
Recent approval of Johnson & Johnson’s dapoxetine in Sweden and Finland put field back on the radar.
J&J Projects Nine NME Filings By 2010, Keeping Pace With Previous Years
With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010
J&J Projects Nine NME Filings By 2010, Keeping Pace With Previous Years
With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010